Valneva builds on traveler's vaccine franchise with €45m Dukoral buy
This article was originally published in Scrip
Executive Summary
France's Valneva has cemented its position in the traveler's vaccine market, acquiring Crucell's cholera and traveler's diarrhea vaccine Dukoral for €45m.